DUBLIN, March 27, 2013 /PRNewswire/ --
Research and Markets announces the addition of " China Insulin Industry Report, 2012-2015" to its catalogue.
Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so. Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China's insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011. Key Topics Covered:1. Insulin Overview 1.1 Definition 1.2 Classification 1.3 Industry Chain 2. Global Insulin Market Development 2.1 Status Quo 2.2 Supply and Demand 2.3 Product R&D 2.4 Competition Pattern 2.5 Development Trend 3. China Insulin Market Development 3.1 Status Quo 3.2 Supply and Demand 3.3 Export 3.4 Import 3.5 Competition Pattern 3.6 Price 3.7 Policy 3.8 Development Trend 4. Key Insulin Manufacturers Companies Mentioned - Eli Lilly and Company - Gan & Lee Pharmaceuticals - Nanjing Xinbai Pharmaceutical - Novo Nordisk - Sanofi Group - Tonghua Dongbao Pharmaceutical - Wanbang Biopharmaceuticals For more information please visit Research and Markets. About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact Details Research and Markets Laura Wood, Senior Manager. press(at)researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals SOURCE Research and Markets